Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker
Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins...
Saved in:
| Published in: | BMC cancer Vol. 10; no. 1; p. 114 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
26-03-2010
BioMed Central BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood.
Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays.
A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, alpha1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.
Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. |
|---|---|
| AbstractList | Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, [alpha]1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. Background Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Methods Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. Results A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, [alpha]1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Conclusions Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. BACKGROUNDBreast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. METHODSPlasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. RESULTSA total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, alpha1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. CONCLUSIONSOur study suggests that BTD is a potential serological biomarker for the detection of breast cancer. Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, alpha1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. Abstract Background Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Methods Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. Results A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Conclusions Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. Doc number: 114 Abstract Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. BACKGROUND: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood. METHODS: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays. RESULTS: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels. CONCLUSIONS: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer. |
| ArticleNumber | 114 |
| Audience | Academic |
| Author | Yu, Myeong-Hee Ahn, Younghee Kim, Yong-Hak Noh, Dong-Young Lee, Jong Won Kim, Joon Kang, Un-Beom Lee, Cheolju |
| AuthorAffiliation | 3 School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea 4 Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea 1 Life Sciences Division, Korea Institute of Science and Technology, Seoul 136-791, Korea 2 Functional Proteomics Center, Korea Institute of Science and Technology, Seoul 136-791, Korea |
| AuthorAffiliation_xml | – name: 4 Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea – name: 2 Functional Proteomics Center, Korea Institute of Science and Technology, Seoul 136-791, Korea – name: 1 Life Sciences Division, Korea Institute of Science and Technology, Seoul 136-791, Korea – name: 3 School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea |
| Author_xml | – sequence: 1 givenname: Un-Beom surname: Kang fullname: Kang, Un-Beom organization: Life Sciences Division, Korea Institute of Science and Technology, Seoul 136-791, Korea – sequence: 2 givenname: Younghee surname: Ahn fullname: Ahn, Younghee – sequence: 3 givenname: Jong Won surname: Lee fullname: Lee, Jong Won – sequence: 4 givenname: Yong-Hak surname: Kim fullname: Kim, Yong-Hak – sequence: 5 givenname: Joon surname: Kim fullname: Kim, Joon – sequence: 6 givenname: Myeong-Hee surname: Yu fullname: Yu, Myeong-Hee – sequence: 7 givenname: Dong-Young surname: Noh fullname: Noh, Dong-Young – sequence: 8 givenname: Cheolju surname: Lee fullname: Lee, Cheolju |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20346108$$D View this record in MEDLINE/PubMed |
| BookMark | eNptk12L3CAUhkPZ0v1o73tVhEJLL7LVmERzU1i2XwMLhX5ci9FjxmkSp-osnZ_Rf1yzs51OliEXij4-yntOzrOT0Y2QZc8JviSE129JyUhelJjlBOeElI-ys_3SycH8NDsPYYUxYRzzJ9lpgWlZE8zPsj_vrTHgYYxW9mjtnbG9HTvkDGo9yBCRkqMCj9a9DIOciAhuANRukQ0uujXkymnQSBpjRxu3KMqumxQDxKXTyMMtyD6g1rqYAC0DIBmQfOBP24P0P8E_zR6bxMOz-_Ei-_Hxw_frz_nNl0-L66ubvK05iTmjvMJVbQrS8DRvykoxQw02kuFWFRVvGea8JkQBgDLaANHAGK20bo1J6EW22Hm1kyux9jZdvxVOWnG34HwnpI9W9SCobOrKaGgokNIYLoGppmokqxpaNLJOrnc713rTDqBVitPLfiad74x2KTp3K4r0QkxpElzvBFMMxwXzHeUGMZVXTOUVBItU_WR5ff8M735tIEQx2KCg7-UIbhMEo-m5FSUkkS8fkCu38WPKO7mK1Bm8rPB_qpMpBTsal-5Wk1NcFUWFi7LAk-vyCJU-DYNVqWFTS8H8wJvZgcRE-B07uQlBLL59nbOvDthl6qS4DK7fROvGMAfxDlTeheDB7MO7C4fXx-J6cVi1_YF_fwf9C0bXETg |
| CitedBy_id | crossref_primary_10_1016_j_clinbiochem_2024_110776 crossref_primary_10_1002_pmic_201100519 crossref_primary_10_1016_j_jprot_2016_07_031 crossref_primary_10_4155_bio_14_227 crossref_primary_10_4174_astr_2024_106_4_195 crossref_primary_10_1021_acsbiomaterials_2c00499 crossref_primary_10_15252_msb_20145728 crossref_primary_10_1002_pmic_201200563 crossref_primary_10_1155_2014_260348 crossref_primary_10_1039_c3ay26616h crossref_primary_10_1155_2012_169416 crossref_primary_10_1038_s41398_019_0605_4 crossref_primary_10_4155_bio_2018_0225 crossref_primary_10_1038_s41598_023_38079_9 crossref_primary_10_1002_prca_201300084 crossref_primary_10_1080_13102818_2017_1358669 crossref_primary_10_1002_mabi_202200390 crossref_primary_10_1038_ncomms8726 crossref_primary_10_1371_journal_pone_0017213 crossref_primary_10_1002_pmic_201000018 crossref_primary_10_1186_s13058_023_01616_5 crossref_primary_10_1021_pr100529t crossref_primary_10_7717_peerj_5285 crossref_primary_10_1002_mas_21362 crossref_primary_10_1016_j_genrep_2020_100658 crossref_primary_10_1002_mas_20356 crossref_primary_10_1016_j_nbt_2012_11_011 crossref_primary_10_1007_s10549_022_06527_1 crossref_primary_10_3389_fimmu_2024_1342912 crossref_primary_10_1002_pmic_201200497 crossref_primary_10_1093_ijnp_pyv100 crossref_primary_10_1016_j_jprot_2012_11_004 crossref_primary_10_1002_sim_6945 crossref_primary_10_3390_ijms25126578 crossref_primary_10_1109_TCBB_2020_2973386 crossref_primary_10_1016_j_jprot_2011_11_021 crossref_primary_10_1093_hmg_ddw196 crossref_primary_10_1016_j_neuroscience_2018_02_010 crossref_primary_10_1177_1091581816637071 crossref_primary_10_1371_journal_pcbi_1007764 crossref_primary_10_3892_ijmm_2019_4352 crossref_primary_10_5812_jjhr_27207 crossref_primary_10_3858_emm_2012_44_1_003 crossref_primary_10_1371_journal_pone_0040956 crossref_primary_10_1039_C6MB00639F crossref_primary_10_3390_proteomes11010002 |
| Cites_doi | 10.1016/j.jchromb.2004.11.012 10.1002/pmic.200600284 10.1111/j.1349-7006.2004.tb03183.x 10.1002/prca.200800167 10.1016/j.cca.2006.06.030 10.1074/mcp.M500331-MCP200 10.1016/S0009-8981(03)00195-5 10.1038/nbt0806-905 10.1210/me.2005-0001 10.1016/S0009-9120(00)00048-5 10.1038/nbt1235 10.1016/S0140-6736(05)66546-4 10.1002/pmic.200500864 10.1016/S0021-9258(17)37409-4 10.1038/nbt1001-946 10.1186/bcr2247 10.1002/prca.200780049 10.1016/0009-8981(83)90096-7 10.1021/pr0501721 10.1113/jphysiol.2004.080473 10.1039/b507839c 10.1002/prca.200800141 10.1021/pr8007573 10.1021/pr050027n 10.1074/mcp.T600039-MCP200 10.1158/0008-5472.CAN-07-0648 10.1111/j.1075-122X.2006.00273.x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 BioMed Central Ltd. 2010 Kang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2010 Kang et al; licensee BioMed Central Ltd. 2010 Kang et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: 2010 Kang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2010 Kang et al; licensee BioMed Central Ltd. 2010 Kang et al; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/1471-2407-10-114 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Science in Context ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Databases ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 114 |
| ExternalDocumentID | oai_doaj_org_article_3a965fde93e14ff8ae7c959a759329a6 oai_biomedcentral_com_1471_2407_10_114 2691510771 A225024201 10_1186_1471_2407_10_114 20346108 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | South Korea |
| GeographicLocations_xml | – name: South Korea |
| GroupedDBID | --- -A0 0R~ 23N 2VQ 2WC 3V. 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR IPNFZ ISR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 ABVAZ AFNRJ 5PM |
| ID | FETCH-LOGICAL-b681t-7385056f2198738945c7f3f0fa70bc258b7088611ceeecfdfe1de7735ddbff7f3 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Tue Oct 22 15:15:36 EDT 2024 Tue Sep 17 21:27:48 EDT 2024 Wed May 22 07:12:08 EDT 2024 Fri Oct 25 02:46:07 EDT 2024 Thu Oct 10 16:56:51 EDT 2024 Tue Nov 19 21:21:00 EST 2024 Tue Nov 12 22:44:55 EST 2024 Thu Aug 01 19:37:00 EDT 2024 Tue Aug 20 21:58:28 EDT 2024 Thu Nov 21 22:19:28 EST 2024 Sat Sep 28 08:01:46 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b681t-7385056f2198738945c7f3f0fa70bc258b7088611ceeecfdfe1de7735ddbff7f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861033/ |
| PMID | 20346108 |
| PQID | 1021088450 |
| PQPubID | 44074 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3a965fde93e14ff8ae7c959a759329a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2861033 biomedcentral_primary_oai_biomedcentral_com_1471_2407_10_114 proquest_miscellaneous_733295311 proquest_journals_1021088450 gale_infotracmisc_A225024201 gale_infotracacademiconefile_A225024201 gale_incontextgauss_ISR_A225024201 gale_healthsolutions_A225024201 crossref_primary_10_1186_1471_2407_10_114 pubmed_primary_20346108 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-03-26 |
| PublicationDateYYYYMMDD | 2010-03-26 |
| PublicationDate_xml | – month: 03 year: 2010 text: 2010-03-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2010 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 15611012 - J Physiol. 2005 Feb 15;563(Pt 1):23-60 15652811 - J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 10913518 - Clin Biochem. 2000 Apr;33(3):197-202 16613992 - Mol Endocrinol. 2006 Sep;20(9):2010-9 15596044 - Cancer Sci. 2004 Dec;95(12):955-61 16889763 - Clin Chim Acta. 2007 Feb;376(1-2):101-7 16083259 - J Proteome Res. 2005 Jul-Aug;4(4):1104-9 21136776 - Proteomics Clin Appl. 2008 Jan;2(1):23-32 16880987 - Mol Biosyst. 2005 Sep;1(3):229-41 18547033 - Cancer Immun. 2008;8:10 16900126 - Nat Biotechnol. 2006 Aug;24(8):905-8 16212426 - J Proteome Res. 2005 Sep-Oct;4(5):1722-31 19186948 - J Proteome Res. 2009 Mar;8(3):1368-79 12867299 - Clin Chim Acta. 2003 Aug;334(1-2):245-7 17083142 - Proteomics. 2006 Dec;6(23):6326-53 16645986 - Proteomics. 2006 Jun;6(11):3236-42 6883721 - Clin Chim Acta. 1983 Jul 15;131(3):273-81 7509806 - J Biol Chem. 1994 Mar 4;269(9):6566-70 16900146 - Nat Biotechnol. 2006 Aug;24(8):971-83 15894099 - Lancet. 2005 May 14-20;365(9472):1727-41 17804715 - Cancer Res. 2007 Sep 1;67(17):8043-50 16332733 - Mol Cell Proteomics. 2006 Apr;5(4):573-88 19400944 - Breast Cancer Res. 2009;11(2):R22 16848844 - Breast J. 2006 Jul-Aug;12(4):343-8 21136934 - Proteomics Clin Appl. 2009 Jan;3(1):30-40 16854842 - Mol Cell Proteomics. 2006 Nov;5(11):2167-74 11581660 - Nat Biotechnol. 2001 Oct;19(10):946-51 20559449 - Proteomics Clin Appl. 2009 Jul 1;3(7):853-861 AK Yocum (1913_CR17) 2005; 4 H Iwaki (1913_CR5) 2004; 95 WY Lo (1913_CR7) 2007; 376 A Bose (1913_CR24) 2008; 8 G Siriwardana (1913_CR10) 2006; 20 L Anderson (1913_CR21) 2006; 5 U Veronesi (1913_CR1) 2005; 365 YP Yu (1913_CR25) 2007; 67 B Lin (1913_CR14) 2009; 3 L Hartwell (1913_CR4) 2006; 24 R Aebersold (1913_CR3) 2005; 4 S Hu (1913_CR9) 2006; 6 DK Han (1913_CR13) 2001; 19 JC Duche (1913_CR23) 2000; 33 D-H Kim (1913_CR11) 2009; 3 M Toigo (1913_CR15) 2005; 1 J Brand (1913_CR18) 2006; 6 B Wolf (1913_CR26) 1983; 131 L Anderson (1913_CR20) 2005; 563 BK Kim (1913_CR22) 2009; 11 JW Chang (1913_CR12) 2008; 2 RI Somiari (1913_CR6) 2005; 815 R Tuli (1913_CR2) 2006; 12 P Abraham (1913_CR27) 2003; 334 H Cole (1913_CR28) 1994; 269 N Rifai (1913_CR8) 2006; 24 HJ Kim (1913_CR19) 2009; 8 T Liu (1913_CR16) 2006; 5 |
| References_xml | – volume: 815 start-page: 215 issue: 1-2 year: 2005 ident: 1913_CR6 publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2004.11.012 contributor: fullname: RI Somiari – volume: 6 start-page: 6326 issue: 23 year: 2006 ident: 1913_CR9 publication-title: Proteomics doi: 10.1002/pmic.200600284 contributor: fullname: S Hu – volume: 95 start-page: 955 issue: 12 year: 2004 ident: 1913_CR5 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2004.tb03183.x contributor: fullname: H Iwaki – volume: 3 start-page: 30 issue: 1 year: 2009 ident: 1913_CR11 publication-title: Proteomics Clin Appl doi: 10.1002/prca.200800167 contributor: fullname: D-H Kim – volume: 376 start-page: 101 issue: 1-2 year: 2007 ident: 1913_CR7 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2006.06.030 contributor: fullname: WY Lo – volume: 5 start-page: 573 issue: 4 year: 2006 ident: 1913_CR21 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M500331-MCP200 contributor: fullname: L Anderson – volume: 334 start-page: 245 issue: 1-2 year: 2003 ident: 1913_CR27 publication-title: Clin Chim Acta doi: 10.1016/S0009-8981(03)00195-5 contributor: fullname: P Abraham – volume: 24 start-page: 905 issue: 8 year: 2006 ident: 1913_CR4 publication-title: Nat Biotechnol doi: 10.1038/nbt0806-905 contributor: fullname: L Hartwell – volume: 20 start-page: 2010 issue: 9 year: 2006 ident: 1913_CR10 publication-title: Mol Endocrinol doi: 10.1210/me.2005-0001 contributor: fullname: G Siriwardana – volume: 33 start-page: 197 issue: 3 year: 2000 ident: 1913_CR23 publication-title: Clin Biochem doi: 10.1016/S0009-9120(00)00048-5 contributor: fullname: JC Duche – volume: 24 start-page: 971 issue: 8 year: 2006 ident: 1913_CR8 publication-title: Nat Biotechnol doi: 10.1038/nbt1235 contributor: fullname: N Rifai – volume: 365 start-page: 1727 issue: 9472 year: 2005 ident: 1913_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(05)66546-4 contributor: fullname: U Veronesi – volume: 6 start-page: 3236 issue: 11 year: 2006 ident: 1913_CR18 publication-title: Proteomics doi: 10.1002/pmic.200500864 contributor: fullname: J Brand – volume: 269 start-page: 6566 issue: 9 year: 1994 ident: 1913_CR28 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)37409-4 contributor: fullname: H Cole – volume: 19 start-page: 946 issue: 10 year: 2001 ident: 1913_CR13 publication-title: Nat Biotechnol doi: 10.1038/nbt1001-946 contributor: fullname: DK Han – volume: 11 start-page: R22 issue: 2 year: 2009 ident: 1913_CR22 publication-title: Breast Cancer Res doi: 10.1186/bcr2247 contributor: fullname: BK Kim – volume: 2 start-page: 23 issue: 1 year: 2008 ident: 1913_CR12 publication-title: Proteomics Clin Appl doi: 10.1002/prca.200780049 contributor: fullname: JW Chang – volume: 131 start-page: 273 issue: 3 year: 1983 ident: 1913_CR26 publication-title: Clin Chim Acta doi: 10.1016/0009-8981(83)90096-7 contributor: fullname: B Wolf – volume: 4 start-page: 1722 issue: 5 year: 2005 ident: 1913_CR17 publication-title: J Proteome Res doi: 10.1021/pr0501721 contributor: fullname: AK Yocum – volume: 563 start-page: 23 issue: Pt 1 year: 2005 ident: 1913_CR20 publication-title: J Physiol doi: 10.1113/jphysiol.2004.080473 contributor: fullname: L Anderson – volume: 1 start-page: 229 issue: 3 year: 2005 ident: 1913_CR15 publication-title: Mol Biosyst doi: 10.1039/b507839c contributor: fullname: M Toigo – volume: 3 start-page: 853 issue: 7 year: 2009 ident: 1913_CR14 publication-title: Proteomics Clin Appl doi: 10.1002/prca.200800141 contributor: fullname: B Lin – volume: 8 start-page: 1368 issue: 3 year: 2009 ident: 1913_CR19 publication-title: J Proteome Res doi: 10.1021/pr8007573 contributor: fullname: HJ Kim – volume: 4 start-page: 1104 issue: 4 year: 2005 ident: 1913_CR3 publication-title: J Proteome Res doi: 10.1021/pr050027n contributor: fullname: R Aebersold – volume: 5 start-page: 2167 issue: 11 year: 2006 ident: 1913_CR16 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.T600039-MCP200 contributor: fullname: T Liu – volume: 67 start-page: 8043 issue: 17 year: 2007 ident: 1913_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-0648 contributor: fullname: YP Yu – volume: 12 start-page: 343 issue: 4 year: 2006 ident: 1913_CR2 publication-title: Breast J doi: 10.1111/j.1075-122X.2006.00273.x contributor: fullname: R Tuli – volume: 8 start-page: 10 year: 2008 ident: 1913_CR24 publication-title: Cancer Immun contributor: fullname: A Bose |
| SSID | ssj0017808 |
| Score | 2.222164 |
| Snippet | Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer.... Background Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast... Doc number: 114 Abstract Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker... BACKGROUNDBreast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast... BACKGROUND: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast... Abstract Background Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 114 |
| SubjectTerms | Adult Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biotin Biotinidase - biosynthesis Biotinidase - blood Biotinidase - genetics Blood plasma Blotting, Western Breast cancer Breast Neoplasms - blood Breast Neoplasms - enzymology Breast Neoplasms - genetics Breast Neoplasms - pathology Care and treatment Chromatography, Liquid Development and progression Female Genetic aspects Genetic markers Genetic screening Health aspects Humans Identification and classification Isotope Labeling - methods Mammography Medical research Methods Middle Aged Plasma Proteins Proteome - metabolism Proteomics Tandem Mass Spectrometry |
| SummonAdditionalLinks | – databaseName: BioMedCentral dbid: RBZ link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgL70eggIWQEIeI2E7iROLS0lZwgEMLEuJi-VlWKslqkz30Z_CPmUmy0XrpBXFdT7LyeOabiT3-hpDXRniTGSFTy51Icw3frFWZh9Rlug6Bc2S5w62LM_nle3V0vE2Ts3OCz6ryHQP4xDMAiYjBsGf1DfhkyNGaTw9_zCcGshq6z83SmyPJK96wc7f9IgpJA3P_3_i8FaDi4smtaHRy51_mcZfcnnJOejAayT1yzTf3yc3P06n6A_L7aOqSAt5-Qccu3hDRaBuowZr1nlq0jRVdQqr9S9OB2wFmRs0lXXRt3y59ilfjHdUhLAAjLmmvcSf7nI4NqinyRIGdU1BIDwIOQifVHdU770d9YbnQ6iH5dnL89cPHdGrVkJqyYn2KnDiQSgWOexiQA-WFlUGELGiZGcuLykiAs5IxiMneBhc8c15KUThnQgDRR2SvaRv_hNACoqUN4LxG5nlRmxriqbEs1762hgeekPfR6qnlSMuhkCg7HgGfVah2hWpX4xXshLzdLPb85DBSlVfIHqI1RP8w_ADrqibPVkLXZRGcr4VneQiV9tLWRa1lAalxrcuEvERbUuO91hlQ1AEgKSZIGUvIq0EC6TgarPc51-uuU5_OTiOhN5NQaGFyVk_XJ0BpyOAVSe5HkoAXNh7eGLWa8KpT2OAdFigvsoTQeRifxBq8xrfrTkkB8wHIhjc8Hl1gVgzPBPL2VwmRkXNEmotHmsXPgcycg1VkQjz9v1V9Rm6NZR0i5eU-2etXa_-cXO_c-sUAE38AsJxiwA priority: 500 providerName: BioMedCentral – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI9gB8QF8U1hQISQEIdqTdI2rcRlsE1wgAMDiVuUz-1Jo3167Tvsz-A_xm76qmUgceHauB-xHdtN7J8JeW2EN4URMrfcibzU8M_a1GXIXaHbEDhHlDvcujiVX340R8cIk7O0-sKcsAgPHBl3IHRbV8H5VnhWhtBoL21btVpWEHm0OoJtF_XuZ2o-P5DN1IuOgenF8wO5O6Bs6oPlGlogxq5Xul8kDmrC8f_TWl9xV2kq5RXfdHKX3JmDSnoYJ3OP3PDdfXLr83xs_oD8OprboMByvqCxTTe4LNoHajApfaQWhb-ha4ilf2o6gTfAx1JzSVdDP_Zrn2Ptu6M6hBUYgUs6atyqPqOxAzVFIChQZApzHIHAgW-keqD62vORBZgPtHlIvp8cf_vwMZ97MeSmbtiYI-gNxEqB4yYFBDllZWUQoQhaFsbyqjES7FXNGDhdb4MLnjkvpaicMyEA6SOy1_Wdf0JoBe7QBlidRpZl1ZoWHKaxrNS-tYYHnpF3iUDUOuJuKETCTkdgUSqUp0J5qlhjnZG3O_ktd04jTf0X2vco4OQN0wXQQDVroPqXBmbkJaqHioWri8VQh2AqMQIqWEZeTRSIt9FhQs-Z3g6D-nT6NSF6MxOFHiZn9VwfAUxDiK6Ecj-hBINg0-GdnqrZIA0KO7iDgMqqyAhdhvFOTLLrfL8dlBQwH7DJ8ITHUasXxvBCIDB_kxGZ6HvCuXSkW51PaOUctKIQ4un_YPUzcjtmb4ic1_tkb9xs_XNyc3DbF9P6_w1Yjl9j priority: 102 providerName: Directory of Open Access Journals |
| Title | Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20346108 https://www.proquest.com/docview/1021088450 https://search.proquest.com/docview/733295311 http://dx.doi.org/10.1186/1471-2407-10-114 https://pubmed.ncbi.nlm.nih.gov/PMC2861033 https://doaj.org/article/3a965fde93e14ff8ae7c959a759329a6 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa6PVRcEJRXoBQLISEO6SZxEjsSlz4FhyLUgoS4WLZjb1faTVab7KE_g3_MTB6ruuXEJYd4nMSeZ-yZz4R80MzqSDMemqRkYargn1XkqQvLSBXOJQmi3OHSxTX_9kucnSNMTjbWwnRJ-0bPj6rF8qia33S5laulmY55YtPvl6eJAKfP2HRCJhAbjr_ow9YBF5EY9yNFPo3B-uIWAkeDA8E_ov9GDFHGxb0a94XnmjoE_4d2-o6j8pMo73iliyfk8RBO0uP-s5-SHVvtk73LYcP8GflzNhyAAoq8oP0B3eCsaO2oxnT0lhpk-5quIIpeKtrBNsDHUn1L503d1isbYtV7SZVzc1D_W9oqXKSe0f7saYoQUCDCFMbYAkEJXpGqhqp7z8cpwEyg9XPy8-L8x-mXcDiFIdS5iNsQ4W4gSnIJLk9AeJNmhjvmIqd4pE2SCc3BUuVxDO7WGlc6G5eWc5aVpXYOSF-Q3aqu7CtCM3CExoFeap6mWaELcJXaxKmyhdGJSwLy2WOIXPWIGxIxsP0WUEeJrJXIWtlXVwfk08i_bc-uReT_oD1BBntv6G7U65kcZE0yVeSZK23BbJw6J5TlpsgKxTOIeguVB-QdiofsS1a3tkIeg5HE2CeKA_K-o0CkjQpTeWZq0zTy6_WVR_RxIHI1DM6ooTICJg3BuTzKA48STIHxm0c5lYMpaiSe3Q4MSrMoIHTbjD0xva6y9aaRnMF4wBrDE172Ur2dmFFZAsI9efdmzm8Bte1wygc1ff3fPd-QR32yBguT_IDstuuNfUsmTbk57NZO4Hp18vuw0_-_Do1fmQ |
| link.rule.ids | 108,230,315,729,782,786,866,887,2106,24946,27933,27934,53800,53802,75821,75822 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokYAL70KgUAshIQ7pJnESOxKX0oda0a0QLRI3y3bsZaXdZLXZPfRn8I-ZyWNVF0697kyysj3zzcSe-UzIR82sjjTjoUlKFqYKvllFnrqwjFThXJIgyx1uXVzyi1_i6BhpcrKhF6Yt2jd6ul_N5vvV9HdbW7mYm9FQJzb6Pj5MBAR9xkZb5D74axQNH-n94QEXkRhOJEU-igF_8RCBI-RA-o_8vxFDnnFxq8t95gWnlsP_X6S-Ear8MsobcenkyR1H9JQ87hNRetCJn5F7tnpOHoz7o_YX5M9Rf3UKQMCMdld7Q5ijtaMaC9lX1KDBLOkC8u-5oi3hAwyS6ms6bepVvbAh9suXVDk3BeC4piuF29sT2t1aTZE8CoyfwtysQKGEeEpVQ9Wt9-PUYQ3R8iX5eXJ8dXga9vc3hDoX8SpEohzIr1yCGxuQGKWZ4Y65yCkeaZNkQnPAuDyOIVBb40pn49JyzrKy1M6B6g7ZrurKviY0gxBqHHi05mmaFbqAIKtNnCpbGJ24JCBfvIWUi46rQyJ7ti8BR5ZoEhJNQnZ92QH5PKz75slWIvL_6H5Fw_D-of2hXk5kv6aSqSLPXGkLZuPUOaEsN0VWKJ5BvlyoPCB7aFaya3bdoIw8AHjFrCmKA_Kh1UCOjgqLgCZq3TTy7PKHp_SpV3I1DM6ovqcCJg1pvTzNXU8TQMT44sG-ZQ9ijcRb32GB0iwKCN2I8UkszKtsvW4kZzAewHF4w6vOGzYTMzhZQLjnJ97M-RJwj5bhvHeHN3d-co88PL0an8vzs4tvb8mjruSDhUm-S7ZXy7V9R7aacv2-xY2_YhtzFA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZokSouvCmBQi2EhDikeTiJE4lL6XZFBa0qChI3y3bsZaXdZLXJHvoz-MfM5LGqCye4rsdZ2Z75ZmyPvyHkrWJGhYpxX8cl8xMJe9Y8S6xfhrKwNo6R5Q6PLq74xY98coo0OdtSX13Svlbzo2qxPKrmP7vcytVSB2OeWHB5fhLn4PQZC1alDXbIXbDZMB436sMFAs_DfLyVzLMgAgzGiwSOsANbAOQADhlyjee3XrovHAfV8fj_idY33JWbSnnDN00f_MeoHpL7Q0BKj3uRR-SOqR6TvfPhyv0J-TUZSqgAFCxoX-Ib3B2tLVWY0N5SjYqzpiuIw5eSdsQPMFCqrum8qdt6ZXx8N19Sae0cAOSathKPuWe0r15NkUQKjIDC_LQgUIJfpbKh8tb3cfowl2j9lHyfnn47-eQPdRx8leVR6yNhDsRZNsYDDgiQklRzy2xoJQ-VjtNcccC6LIrAYRttS2ui0nDO0rJU1oLoM7Jb1ZV5TmgKrlRbsGzFkyQtVAHOVukokabQKraxRz44iylWPWeHQBZttwUMWqBaCFQL0b_P9sj7ce23PbuWPPuL7EdUDucfuh_q9UwM6yqYLLLUlqZgJkqszaXhukgLyVOImwuZeeQQVUv0j163aCOOAWYxegojj7zpJJCro8JkoJncNI04u_rqCL0bhGwNg9NyeFsBk4b0Xo7kgSMJYKLd5lHHxQBmjcDq77BASRp6hG6bsScm6FWm3jSCMxgP4Dl8Yb-3iO3EjIbmEe7YijNzbguYSMd0PpjEi3_ueUj2LidT8eXs4vNLcq_P_GB-nB2Q3Xa9Ma_ITlNuXnfQ8RvPZHWU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+profiling+of+breast+cancer+plasma+proteome+by+isotope-coded+affinity+tagging+method+reveals+biotinidase+as+a+breast+cancer+biomarker&rft.jtitle=BMC+cancer&rft.au=Kang%2C+Un-Beom&rft.au=Ahn%2C+Younghee&rft.au=Lee%2C+Jong+Won&rft.au=Kim%2C+Yong-Hak&rft.date=2010-03-26&rft.eissn=1471-2407&rft.volume=10&rft.spage=114&rft.epage=114&rft_id=info:doi/10.1186%2F1471-2407-10-114&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |